JPH06107550A - Anti-inflammatory agent for oral administration - Google Patents

Abstract

PURPOSE:To provide a peroral anti-inflammatory agent containing hyaluronic acid as an active component, having little side effect and high safety and useful for the treatment of inflammation of mucous membrane in amygdalitis, pharyngitis and larynxitis. CONSTITUTION:Hyaluronic acid is used as an active component. The agent can be prepared in various forms such as jelly, a drop-like aqueous agent or a saliva-soluble capsule. Hyaluronic acid is a kind of acidic mucopolysaccharides and widely present between the tissues and in the body fluid of vertebrate animal. Hyaluronic acid can be bonded to the inflammation part of the mucous membrane from the oral cavity to the upper respiratory tract and cure the inflammation by oral administration of hyaluronic acid. In a connective tissue component in a wound healing stage, hyaluronic acid is developed first and, according to the elimination of the acid, chondroitin sulfate is developed to synthesize a collagen, form cicatrices and heal the wound. Early recovery is possible because of the adhesion of hyaluronic acid to the inflammatory mucous membrane, the promotion of exudation of healing substance and the protection of the inflammatory mucous membrane.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION The oral anti-inflammatory agent of the present invention relates to medical treatment for treating oral mucosa and pharyngeal / larynx mucosa.

[0002]

Description of the Prior Art Hyaluronic acid is widely present between tissues of vertebrates and in body fluids. Especially in humans, it is found in high concentrations in the umbilical cord, synovial fluid and vitreous. Currently, topical applications of hyaluronic acid include ophthalmic surgery auxiliary agents, eye drops, and therapeutic agents for degenerative joints.

Hyaluronic acid has the pharmacological effects of suppressing the function of polymorphonuclear leukocytes, suppressing contact between lymphocytes and target cells,
It is said to have migration of macrophages and suppression of phagocytosis, angiogenic activity of low molecular weight hyaluronic acid, radical scavenger action, and cell proliferation action. However, hyaluronic acid itself has no physiological activity, and its physical properties are considered to be an inducer of these physiological activities. That is, for example, it is considered that hyaluronic acid serves as a carrier for a wound healing substance or an inflammatory substance that is a physiologically active substance and is deeply involved in the wound healing process and the inflammation process.

In Japan, it is classified as a drug having no medicinal effect rather than being an aqueous injection, and in the US as a medical device. The conventionally used 1% aqueous solution of hyaluronic acid has excellent physical properties in viscosity and elasticity, and is generally called a viscoelastic substance.

[0005]

[Problems to be Solved by the Invention] Mucosa from the upper respiratory tract or upper esophagus to the oral cavity during tonsils, pharynx, laryngitis and respiratory tract diseases Is present in hyaluronic acid.

[0006] Exudation of hyaluronic acid may be inhibited. For example,
Bromhexine hydrochloride and However, bromhexine hydrochloride, methyl cysteine, etc. increase secretions that make sputum easier to cut, and reduce the molecular weight of acidic mucopolysaccharide, which is one of the components of sputum, to cut sputum. It is said to improve.

[0007]

[Means for solving the problem] Therefore, hyaluronic acid, which is one of the acidic mucopolysaccharides, is orally administered, and hyaluronic acid is adhered to the inflammatory site of the mucous membrane from the mouth to the upper respiratory tract to cure the site. It is something to try. In particular, since hyaluronic acid has adhesiveness with inflammatory proteins, the administered hyaluronic acid specifically adheres to the site of inflammation. Hyaluronic acid that has not adhered is decomposed and absorbed through the esophagus, stomach, and intestines.

Hyaluronic acid as a base is well soluble in water. The hyaluronic acid is easy to take when it is used as an aqueous agent, jelly, candy, or saliva-soluble capsule.

Although hyaluronic acid is known to be a wound healing substance, the present invention is characterized by oral administration of hyaluronic acid to treat mucosal inflammation in tonsils, pharynx and laryngitis.

[0010]

It is known that hyaluronic acid first appears in connective tissue components in the process of wound healing, and then disappears, chondroitin sulfate appears, and collagen is synthesized to scar and heal the wound. In other words, it is considered necessary that hyaluronic acid, which carries a wound healing substance, is present in the process of repairing the tissue after tissue damage due to some cause, for example, inflammation. Since purified hyaluronic acid has a property of covalently binding to a protein, it specifically adheres to mucous membranes under inflammation in which inflammatory proteins are present. It is known that sodium hyaluronate has a strong water retention capacity and has a hydration volume about 1,000 times the dry matter volume. It has a non-Newtonian viscoelastic property during water retention, and has the role of tissue protection and lubricant. In the present invention, all of these effects are applied, and the present invention is used for treating oral mucosa and larynx mucosa.

[0011]

Example 1 10 mg of sodium hyaluronate was dissolved in 1 ml of distilled water together with 90 mg of sodium chloride to prepare an aqueous solution of sodium hyaluronate. The sodium hyaluronate used had an average molecular weight of about 900,000 daltons and was extracted and purified from chicken caps. When the present inventor himself took the medicine to treat inflammation of the mucous membrane in laryngitis, he felt a sticky feeling on the inflamed mucous membrane immediately after drinking, and stopped coughing on the next day, and was relieved.

[0012]

Example 2 A 3% sodium hyaluronate aqueous solution having an average molecular weight of about 1.2 million daltons and extracted and purified from a chicken cob was prepared into a jelly form. Soak in absolute alcohol for 24 hours,
The jelly-like surroundings were dehydrated and hardened. When I put this hyaluronic acid jelly in my mouth, it was almost tasteless,
It swelled slowly and contained water.

[0013]

[Example 3] A 3% sodium hyaluronate aqueous solution having an average molecular weight of approximately 1.2 million daltons was extracted and purified from a chicken cob and formed into a jelly plate. It was soaked in anhydrous alcohol for 24 hours to further dehydrate and harden the jelly-like surroundings. Roll the solidified sodium hyaluronate with starch syrup, dry,
Made candy-shaped. When this hard candy of hyaluronic acid was put in the mouth, it was sweet and swollen slowly, hydrated and dissolved.

[0014]

[Example 4] A 2% aqueous solution of sodium hyaluronate extracted and purified from chicken combs having an average molecular weight of about 1.2 million daltons was prepared into a jelly form. This was made into a capsule that dissolves in the mouth.

[0015]

As described above, the oral anti-inflammatory drug containing hyaluronic acid as a main component of the present invention can treat mucosal inflammation in tonsils, pharynx and laryngitis. Since the drug itself is considered to have no pharmacological activity, it has few side effects and is safe. In particular, if it is taken in the form of jelly or candy, it can be easily taken by old people and children. Hyaluronic acid is a polysaccharide and a substance that can be used as a soothing candy. The oral anti-inflammatory agent of the present invention containing hyaluronic acid as a main component adheres to inflamed mucosa, promotes exudation of a healing substance, and protects the inflamed mucosa, so that early recovery of the patient can be expected.

Claims (5)

[Claims] 1. An oral anti-inflammatory agent containing hyaluronic acid as an active ingredient. 2. An oral anti-inflammatory agent containing hyaluronic acid as an active ingredient in the form of a jelly. 3. An oral anti-inflammatory agent which comprises hyaluronic acid as an active ingredient and has a candy-like dosage form. 4. An oral anti-inflammatory agent containing hyaluronic acid as an active ingredient in the form of an aqueous formulation. 5. An oral anti-inflammatory agent comprising hyaluronic acid as an active ingredient and encapsulated in capsules.